Academic Press Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology: From Basic Research to Advanced Study

Product Description Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications―arrhythmias, heart failure, and even death. Review A comprehensive, translational overview of the cardiovascular toxicity and therapeutic modalities targeting cardio-oncology From the Back Cover Anti-cancer treatment is associated with serious cardiovascular adverse events including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.<br><br>In view of the growing clinical and healthcare relevance of cancer survivors who are at an elevated risk of dying from cardiovascular diseases, <i>Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study</i> analyses the emerging the field of cardio-oncology; reviewing the recent advancements in the field, how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms, and concepts, which is followed by advanced state-of-art of cardio-oncology. The book starts with a brief introduction on cancer and cardiovascular diseases in cancer patients, as well as the changes observed in the cardiovascular system; which serves to provide a deeper understanding of therapeutic approaches targeting cardio-oncology. It then looks into the pathways and inhibitors involved in cancer immunology, as well as the biochemistry of tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs. The book then concludes with clinical focused chapters, including noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular risk, cardiovascular complication from cancer therapy, novel anticancer drugs related to cardiotoxicity, and principles of cardiovascular rehabilitation.<br><br>Written by leading researches in various disciplines, the book serves as a valuable resource to those who are new to the field, as well as various other specialized scientists, researchers, oncol